<?xml version="1.0" encoding="UTF-8"?>
<p>According to the GRADE approach, only two studies presented high quality, whilst most of the included research showed low-to-moderate quality. Detailed information concerning quality assessment is included in 
 <xref rid="life-11-00214-t001" ref-type="table">Table 1</xref>. According to the RoB 2.0 tool, there were some concerns about the possible risk of bias for included RCTs, mainly affecting the randomization process and data reporting (
 <xref rid="life-11-00214-t002" ref-type="table">Table 2</xref>). Indeed, in the study with randomized, double-blind, placebo-controlled cross-over design [
 <xref rid="B39-life-11-00214" ref-type="bibr">39</xref>] information about the sequence allocation was not available, whilst in the randomized, double-blind, placebo-controlled, between-subjects study [
 <xref rid="B52-life-11-00214" ref-type="bibr">52</xref>] outcome data was not available for all randomized subjects.
</p>
